I honestly do not understand the term as it applies to Generex. Whoever it is, keeps repeating the same thing over and over again. If there was toxic debt, Donohoe, let alone NASDAQ wouldn't give the application a second glance. At least, that's what I think. Any clarification in general terms, not specific to Generex would be appreciated.
All of that aside, we continue to be impressed by the progress that has been made.
(1)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links